Parkinson's disease
Conditions
Brief summary
Change in motor symptoms using the MDS-UPDRS part III from baseline to two weeks after daily tadalafil administration.
Detailed description
All adverse events will be recorded during follow-up. The following specific side effects will be assessed (yes/no): 1) Headache, 2) Dyspepsia, 3) Back pain, 4) Muscle pain, 5) Flushing, 6) Nasal congestion, 7) Unwanted erections, and 8) Changes in libido. Blood pressure (mmHg) and heart rate (bpm) will be measured at baseline and after two weeks., Participant’s evaluation of the burden of the treatment after two weeks follow-up will be measured with a five-point Likert-type item., Participant’s satisfaction on the outcome of treatment after two weeks follow-up will be measured with a five-point Likert scale.
Interventions
DRUGTADALAFIL
Sponsors
Amsterdam UMC Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in motor symptoms using the MDS-UPDRS part III from baseline to two weeks after daily tadalafil administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| All adverse events will be recorded during follow-up. The following specific side effects will be assessed (yes/no): 1) Headache, 2) Dyspepsia, 3) Back pain, 4) Muscle pain, 5) Flushing, 6) Nasal congestion, 7) Unwanted erections, and 8) Changes in libido. Blood pressure (mmHg) and heart rate (bpm) will be measured at baseline and after two weeks., Participant’s evaluation of the burden of the treatment after two weeks follow-up will be measured with a five-point Likert-type item., Participant’s satisfaction on the outcome of treatment after two weeks follow-up will be measured with a five-point Likert scale. | — |
Countries
Netherlands
Outcome results
None listed